Oaktree Acquisition Corp. III Life Sciences (OACC) Competitors $10.45 -0.02 (-0.19%) As of 08/14/2025 01:14 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock OACC vs. CSR, FBRT, ORC, PAX, NOAH, NXRT, AC, GETY, PBT, and AACTShould you be buying Oaktree Acquisition Corp. III Life Sciences stock or one of its competitors? The main competitors of Oaktree Acquisition Corp. III Life Sciences include Centerspace (CSR), Franklin BSP Realty Trust (FBRT), Orchid Island Capital (ORC), Patria Investments (PAX), Noah (NOAH), NexPoint Residential Trust (NXRT), Associated Capital Group (AC), Getty Images (GETY), Permian Basin Royalty Trust (PBT), and Ares Acquisition Corporation II (AACT). These companies are all part of the "trading" industry. Oaktree Acquisition Corp. III Life Sciences vs. Its Competitors Centerspace Franklin BSP Realty Trust Orchid Island Capital Patria Investments Noah NexPoint Residential Trust Associated Capital Group Getty Images Permian Basin Royalty Trust Ares Acquisition Corporation II Centerspace (NYSE:CSR) and Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) are both small-cap trading companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Do insiders & institutionals hold more shares of CSR or OACC? 79.0% of Centerspace shares are owned by institutional investors. 0.4% of Centerspace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is CSR or OACC more profitable? Oaktree Acquisition Corp. III Life Sciences has a net margin of 0.00% compared to Centerspace's net margin of -9.13%. Oaktree Acquisition Corp. III Life Sciences' return on equity of 0.00% beat Centerspace's return on equity.Company Net Margins Return on Equity Return on Assets Centerspace-9.13% -2.81% -1.27% Oaktree Acquisition Corp. III Life Sciences N/A N/A N/A Which has better earnings and valuation, CSR or OACC? Oaktree Acquisition Corp. III Life Sciences has lower revenue, but higher earnings than Centerspace. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCenterspace$260.98M3.53-$10.69M-$1.80-30.56Oaktree Acquisition Corp. III Life SciencesN/AN/AN/AN/AN/A Does the media favor CSR or OACC? In the previous week, Centerspace had 7 more articles in the media than Oaktree Acquisition Corp. III Life Sciences. MarketBeat recorded 9 mentions for Centerspace and 2 mentions for Oaktree Acquisition Corp. III Life Sciences. Oaktree Acquisition Corp. III Life Sciences' average media sentiment score of 1.77 beat Centerspace's score of 1.17 indicating that Oaktree Acquisition Corp. III Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centerspace 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oaktree Acquisition Corp. III Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do analysts prefer CSR or OACC? Centerspace presently has a consensus price target of $69.75, suggesting a potential upside of 26.79%. Given Centerspace's stronger consensus rating and higher possible upside, equities analysts plainly believe Centerspace is more favorable than Oaktree Acquisition Corp. III Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centerspace 0 Sell rating(s) 4 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.63Oaktree Acquisition Corp. III Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryCenterspace beats Oaktree Acquisition Corp. III Life Sciences on 8 of the 12 factors compared between the two stocks. Get Oaktree Acquisition Corp. III Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for OACC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OACC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OACC vs. The Competition Export to ExcelMetricOaktree Acquisition Corp. III Life SciencesInvestment Offices IndustryFinancial SectorNASDAQ ExchangeMarket Cap$234.79M$178.61M$6.46B$9.84BDividend YieldN/AN/A4.18%4.07%P/E RatioN/AN/A14.3625.74Price / SalesN/AN/A1,809.00115.83Price / CashN/A36,712.32127.1459.48Price / BookN/AN/A5.196.15Net IncomeN/A-$160K$1.23B$265.06M7 Day Performance-0.19%0.16%0.84%2.60%1 Month PerformanceN/A-0.08%2.39%2.83%1 Year PerformanceN/A5.17%28.21%25.58% Oaktree Acquisition Corp. III Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OACCOaktree Acquisition Corp. III Life SciencesN/A$10.45-0.2%N/AN/A$234.79MN/A0.00N/ANews CoveragePositive NewsCSRCenterspace4.1975 of 5 stars$53.55-0.9%$70.78+32.2%-25.7%$905.20M$260.98M-29.75470Positive NewsFBRTFranklin BSP Realty Trust4.1313 of 5 stars$10.87-0.1%$14.88+36.8%-11.8%$895.15M$210.45M11.09N/AORCOrchid Island Capital2.5399 of 5 stars$7.15+1.6%N/A-10.2%$892.17M$241.58M35.752,018News CoverageDividend AnnouncementShort Interest ↑PAXPatria Investments2.2989 of 5 stars$13.65-0.9%$14.00+2.6%+17.3%$827.75M$397.50M27.30390NOAHNoah4.0644 of 5 stars$12.15-0.4%$12.00-1.2%+54.9%$807.10M$356.33M12.531,990NXRTNexPoint Residential Trust4.2847 of 5 stars$31.02-1.3%$42.30+36.4%-28.9%$797.46M$259.70M-15.833Analyst ForecastACAssociated Capital Group2.5117 of 5 stars$36.77+2.0%N/A+15.0%$762.22M$13.18M14.5320News CoverageGETYGetty Images2.3433 of 5 stars$1.70-4.5%$4.35+155.9%-45.9%$738.36M$939.29M-8.951,700News CoverageEarnings ReportAnalyst DowngradeGap DownPBTPermian Basin Royalty Trust1.6782 of 5 stars$16.20+3.8%N/A+38.3%$727.10M$26.96M33.06N/ANews CoveragePositive NewsEarnings ReportAACTAres Acquisition Corporation IIN/A$11.40+0.0%N/A+5.8%$704.58MN/A0.00N/ANews CoverageUpcoming Earnings Related Companies and Tools Related Companies Centerspace Competitors Franklin BSP Realty Trust Competitors Orchid Island Capital Competitors Patria Investments Competitors Noah Competitors NexPoint Residential Trust Competitors Associated Capital Group Competitors Getty Images Competitors Permian Basin Royalty Trust Competitors Ares Acquisition Corporation II Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OACC) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oaktree Acquisition Corp. III Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Share Oaktree Acquisition Corp. III Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access